Point72 Takes 9.9% Stake in Iterum Therapeutics

TL;DR

**Point72 just bought nearly 10% of Iterum Therapeutics, big bullish signal!**

AI Summary

Point72 Asset Management, L.P. has reported a significant stake in Iterum Therapeutics plc, holding 1,999,999 ordinary shares, which represents 9.9% of the company's outstanding shares. This filing, dated January 30, 2024, indicates a substantial investment by a major institutional investor. This matters to shareholders because it signals a vote of confidence from a sophisticated fund, potentially attracting more investor interest and positively influencing the stock price of Iterum Therapeutics.

Why It Matters

A large institutional investment like this can boost investor confidence and potentially lead to increased trading volume and stock price appreciation for Iterum Therapeutics.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, generally seen as a positive development that reduces perceived risk.

Analyst Insight

A smart investor would research Iterum Therapeutics plc further, considering this institutional vote of confidence, and potentially look for entry points if the company's fundamentals align with their investment strategy.

Key Numbers

• 1,999,999 — Shares Owned (Point72 Asset Management's total beneficial ownership in Iterum Therapeutics plc.)
• 9.9% — Ownership Percentage (The percentage of Iterum Therapeutics plc's ordinary shares owned by Point72 Asset Management.)
• January 30, 2024 — Event Date (The date on which Point72 Asset Management's ownership crossed the threshold requiring this SC 13G filing.)

Key Players & Entities

• Point72 Asset Management, L.P. (company) — the reporting person acquiring shares
• Iterum Therapeutics plc (company) — the subject company whose shares were acquired
• 1,999,999 (dollar_amount) — number of ordinary shares beneficially owned
• 9.9% (dollar_amount) — percentage of class outstanding owned by Point72
• January 30, 2024 (person) — date of event requiring the filing
• $0.01 (dollar_amount) — par value per ordinary share

Forward-Looking Statements

• Iterum Therapeutics plc's stock price will see increased investor interest due to Point72's significant stake. (Iterum Therapeutics plc) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securitie

Filing Documents

• p24-0546sc13g.htm (SC 13G) — 74KB
• p24-0546exhibit99.htm (EX-99.1) — 7KB
• 0000902664-24-000843.txt ( ) — 83KB

(a)

Item 1(a). Name of Issuer. Iterum Therapeutics plc (the " Issuer ").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. Fitzwilliam Court, 1 st Floor, Leeson Close, Dublin 2 Ireland.

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to ordinary shares, par value $0.01 per share (" Ordinary Shares "), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (" Point72 Associates "); (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc .") with respect to Ordinary Shares held by Point72 Associates; (iii) Cubist Systematic Strategies, LLC (" Cubist Systematic Strategies ") with respect to Ordinary Shares held by an investment fund it manages; and (iv) Steven A. Cohen (" Mr. Cohen ") with respect to Ordinary Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Ordinary Shares, par value $0.01 per share.

(e)

Item 2(e). CUSIP Number. G6333L200 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. CUSIP No. G6333L200 13G Page 7 of 8 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 30, 2024. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Ordinary Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Ordinary Shares. Item 7

View Full Filing

View this SC 13G filing on SEC EDGAR